-transparent.png){kind=logo}
OBJECTIVE To evaluate the activity of 2-chlorodeoxyadenosine (2CdA) in the treatment of patients with Waldenstrom macroglobulinemia. METHODS Uncontrolled phase II trial. METHODS Tertiary, referral cancer center. METHODS Twenty-nine consecutive, symptomatic patients with Waldenstrom macroglobulinemia, of whom 9 were previously untreated. METHODS 2-Chlorodeoxyadenosine was administered as a continuous intravenous infusion at a dose of 0.1 mg/kg body weight per day for 7 days. Only two courses of 2CdA were given and responding patients were then followed without further treatment. RESULTS A total of 17 (59%) patients responded, including all of those who were newly diagnosed and 40% of those who had failed previous therapies. Treatment was well tolerated except for one death in a patient who had presented with severe pancytopenia. With a median follow-up of 7 months, only one responding patient has relapsed. CONCLUSIONS 2-Chlorodeoxyadenosine is a nucleoside analog that was effective in most patients with Waldenstrom macroglobulinemia and was associated with little toxicity.
M A Dimopoulos, and
H Kantarjian, and
E Estey, and
S O'Brien, and
K Delasalle, and
M J Keating, and
E J Freireich, and
R Alexanian
March 2004,
Praxis,
M A Dimopoulos, and
H Kantarjian, and
E Estey, and
S O'Brien, and
K Delasalle, and
M J Keating, and
E J Freireich, and
R Alexanian
June 1961,
Pennsylvania medical journal (1928),
M A Dimopoulos, and
H Kantarjian, and
E Estey, and
S O'Brien, and
K Delasalle, and
M J Keating, and
E J Freireich, and
R Alexanian
January 1955,
La Pediatria,
M A Dimopoulos, and
H Kantarjian, and
E Estey, and
S O'Brien, and
K Delasalle, and
M J Keating, and
E J Freireich, and
R Alexanian
October 2008,
Cancer letters,
M A Dimopoulos, and
H Kantarjian, and
E Estey, and
S O'Brien, and
K Delasalle, and
M J Keating, and
E J Freireich, and
R Alexanian
January 1961,
Bulletin des societes d'ophtalmologie de France,
M A Dimopoulos, and
H Kantarjian, and
E Estey, and
S O'Brien, and
K Delasalle, and
M J Keating, and
E J Freireich, and
R Alexanian
January 2016,
Cancer treatment and research,
M A Dimopoulos, and
H Kantarjian, and
E Estey, and
S O'Brien, and
K Delasalle, and
M J Keating, and
E J Freireich, and
R Alexanian
February 2019,
Journal francais d'ophtalmologie,
M A Dimopoulos, and
H Kantarjian, and
E Estey, and
S O'Brien, and
K Delasalle, and
M J Keating, and
E J Freireich, and
R Alexanian
February 1975,
Die Medizinische Welt,
M A Dimopoulos, and
H Kantarjian, and
E Estey, and
S O'Brien, and
K Delasalle, and
M J Keating, and
E J Freireich, and
R Alexanian
January 2023,
Leukemia & lymphoma,
M A Dimopoulos, and
H Kantarjian, and
E Estey, and
S O'Brien, and
K Delasalle, and
M J Keating, and
E J Freireich, and
R Alexanian
May 2022,
Expert review of anticancer therapy,
